Loading
Pancreatic tumours are packed with a type of white blood cell that shuts down the immune attack. Blocking the signal that recruits them may open the tumour to immunotherapy.
CXCR2-dependent recruitment of granulocytic myeloid-derived suppressor cells is a dominant immunosuppressive mechanism in pancreatic and some head and neck cancers, and CXCR2 inhibition plus checkpoint blockade improved survival in genetically engineered mouse models. Human trials of CXCR1/2 inhibitors with chemotherapy or checkpoint blockade have been small and biomarker-light. The decisive step is patient selection by neutrophil infiltration measured on tissue, not by blood counts alone.
Shares Estimation of the Percentage of US Patients With Cancer Who Are Eligible for and Respond to Checkpoint Inhibitor Immunotherapy Drugs, Single-cell & spatial profiling, Hot vs cold tumours, Cold tumours and the immunosuppressive microenvironment.
Shares Estimation of the Percentage of US Patients With Cancer Who Are Eligible for and Respond to Checkpoint Inhibitor Immunotherapy Drugs, Hot vs cold tumours, Cold tumours and the immunosuppressive microenvironment, No one can predict who responds to immunotherapy.
Shares Estimation of the Percentage of US Patients With Cancer Who Are Eligible for and Respond to Checkpoint Inhibitor Immunotherapy Drugs, Single-cell & spatial profiling, Hot vs cold tumours, Cold tumours and the immunosuppressive microenvironment.
Shares Estimation of the Percentage of US Patients With Cancer Who Are Eligible for and Respond to Checkpoint Inhibitor Immunotherapy Drugs, Hot vs cold tumours, Cold tumours and the immunosuppressive microenvironment, Pancreatic ductal adenocarcinoma.
Shares Estimation of the Percentage of US Patients With Cancer Who Are Eligible for and Respond to Checkpoint Inhibitor Immunotherapy Drugs, Desmoplasia (tumour stroma), Single-cell & spatial profiling, Digital pathology & AI.
Shares Estimation of the Percentage of US Patients With Cancer Who Are Eligible for and Respond to Checkpoint Inhibitor Immunotherapy Drugs, Hot vs cold tumours, Cold tumours and the immunosuppressive microenvironment, No one can predict who responds to immunotherapy.
Shares Single-cell & spatial profiling, Hot vs cold tumours, Digital pathology & AI, No one can predict who responds to immunotherapy.
Shares Single-cell & spatial profiling, Hot vs cold tumours, Digital pathology & AI, No one can predict who responds to immunotherapy.